ADIM
BCYC

Alpha DNA Investment Management’s Bicycle Therapeutics BCYC Stock Holding History

Alpha DNA Investment Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,957
Closed -$562K – 192
2023
Q3 		$562K Buy
+27,957
New +$639K 0.23% 108

Other funds holding BCYC

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Alpha DNA Investment Management's BCYC Position: Q4 2023 in Review

Alpha DNA Investment Management sold out of Bicycle Therapeutics (BCYC) in Q4 2023, closing a stake of 27,957 shares — an estimated $562K sold.

Alpha DNA Investment Management first reported a position in BCYC in Q3 2023 and held it in 1 quarter. The position peaked at $562K in Q3 2023. 101 funds tracked by Wall St. Rank hold BCYC as of Q4 2023.

  • Alpha DNA Investment Management reported no remaining Bicycle Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 27,957 Bicycle Therapeutics shares in Q4 2023, an estimated $562K.
  • Alpha DNA Investment Management first reported a position in Bicycle Therapeutics in Q3 2023 and held it in 1 quarter.
  • Alpha DNA Investment Management's Bicycle Therapeutics position peaked at $562K in Q3 2023.
  • 101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2023.

Based on Alpha DNA Investment Management's 13F filing for Q4 2023, filed 12 Feb 2024.